Get to know our clinical trials
Clinical trial to evaluate the efficacy and safety of lebrikizumab treatment in adults and adolescents with moderate to severe atopic dermatitis.
THE AIM OF THE STUDY IS TO DETERMINE WHETHER AN EXPERIMENTAL DRUG, CALLED LEBRIKIZUMAB, IS HELPFUL IN THE TREATMENT OF ATOPIC DERMATITIS AND TO WHAT EXTENT IT IS SAFE FOR USE IN HUMANS. LEBRIKIZUMAB HAS ALREADY BEEN APPROVED BY THE EUROPEAN MEDICINES AGENCY (EMA), WHICH HAS ASSESSED ITS SAFETY AND EFFICACY, AND WILL BE AVAILABLE FOR USE IN PHARMACIES IN THE FUTURE.
Technical Summary
- UNBLINDED PHASE IIIB STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB TREATMENT IN ADULTS AND ADOLESCENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS.
- Code EudraCT: 2023-508235-31
- Protocol number: M-17923-34
- Promoter: Almirall S.A
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.